For older adults with type 2 diabetes, the risk for dementia seems similar with sodium-glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

Type 2 diabetes (T2D) and heart health have a complex and dependent relationship. New data presented at ACC 2026 suggests that dulaglutide may be doing something far more dramatic than managing ...

For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with ...

Dulaglutide reduces liver fat content in patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease, when used in combination with standard T2D treatment. Although previous data show ...

Dulaglutide injection should be given subcutaneously in the abdomen, thigh or upper arm once e every week at any time of the day. The initial dose is 0.75 mg once a week. The dose can be increased to ...

INDIANAPOLIS, June 9, 2019 /PRNewswire/ -- Detailed results from REWIND, the Trulicity ® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major cardiovascular ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. NEW ORLEANS — Young people with type 2 diabetes taking ...

Eli Lilly (LLY 0.71%) needs a big win to offset recent high profile patent expirations and that's why the company's recent release of data for its promising GLP-1 diabetes drug dulaglutide is so ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

BARCELONA, Spain — Dulaglutide (Trulicity, Lilly) treatment reduces binge eating in patients with type 2 diabetes and binge eating disorder, and was associated with rapid and significant reductions in ...